The efficacy of immunotherapy, particularly blockade of the PD-1/PD-L1 pathway, in HNSCC patients was recently demonstrated [20], although HNSCC was initially recognized as an immunosuppressive tumor from the perspective of lower lymphocyte count, spontaneous apoptosis of cytotoxic T lymphocytes (CTLs), and poor antigen-presenting function in patient blood samples [21]. This evidence concerns the gene CD274 and neoplasm.